圣诺生物(688117) - 2025 Q2 - 季度业绩预告

Announcement Statement Chengdu Senor Bio-Technology Co., Ltd. announces its 2025 semi-annual performance forecast, board guarantees content accuracy - Chengdu Senor Bio-Technology Co., Ltd. issues a voluntary disclosure announcement for its 2025 semi-annual performance forecast, with the board guaranteeing the truthfulness, accuracy, and completeness of the content[1] 2025 Semi-Annual Performance Forecast Overview The company forecasts significant year-over-year growth in H1 2025 net profit and non-recurring net profit Forecast Period This performance forecast covers the financial period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[2] Key Financial Indicator Forecast The company forecasts substantial year-over-year growth in H1 2025 net profit and non-recurring net profit Key Performance Forecast Indicators for H1 2025 | Indicator | Estimated Amount (10,000 CNY) | Year-over-Year Increase (10,000 CNY) | Year-over-Year Growth (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent | 7,702.75 to 9,414.48 | 5,523.99 to 7,235.71 | 253.54 to 332.10 | | Net Profit After Non-Recurring Items | 7,734.64 to 9,453.45 | 5,822.44 to 7,541.25 | 304.49 to 394.38 | Audit Status This performance forecast is a preliminary, unaudited calculation by the finance department - This performance forecast is unaudited by a certified public accountant and represents preliminary calculations by the finance department[4] Review of Prior Year's Performance This section reviews the company's H1 2024 financial performance, providing a baseline for the current forecast Key Financial Data for H1 2024 | Indicator | Amount (10,000 CNY) | | :--- | :--- | | Net Profit Attributable to Parent | 2,178.76 | | Net Profit After Non-Recurring Items | 1,912.20 | | Total Profit | 2,329.99 | | Earnings Per Share (CNY/share) | 0.19 | Main Reasons for Performance Change Performance growth is driven by peptide industry trends, expanded marketing, and strong peptide API sales - The company closely followed peptide industry development trends, continuously expanded domestic and international marketing, and intensified product sales efforts[6] - In the first half of 2025, the company's peptide API business performed well, driving a significant year-over-year increase in net profit[6] Risk Warning Investors are cautioned about unaudited preliminary data and revenue recognition uncertainties Unaudited Performance Forecast This performance forecast is a preliminary, unaudited calculation, subject to potential adjustments - This performance forecast represents preliminary calculations by the finance department and has not been audited by a certified public accountant[8] Revenue Recognition Uncertainty Certain orders face revenue recognition uncertainty within the reporting period due to factors like shipment and logistics - Revenue recognition for some orders within the reporting period is uncertain due to factors such as shipment and logistics[8] Other Matters The company reminds investors that forecast data is preliminary; final figures will be in the 2025 semi-annual report, caution advised - The forecast data is preliminary, and final financial figures will be based on the 2025 semi-annual report[9] - Investors are advised to exercise caution regarding investment risks[9]